Armata Pharmaceuticals, Inc. (ARMP) News & EventsARMPArmata Pharmaceuticals, Inc.

Armata Receives $3.7M Non-Dilutive Funding for AP-SA02 Phase 3 Development

Armata Pharmaceuticals announced that it has received an additional $3.7M in non-dilutive funds from the U.S. Department of War to support activities associated with the Phase 3 development program for AP-SA02. Importantly, the $3.7M represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium and managed by the Naval Medical Research Command - Naval Advanced Medical Development with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. This funding follows the $28.7M previously provided, bringing cumulative non-dilutive DoW funding under the award to approximately $32.4M and underscoring the U.S. government's continued interest in advancing the AP-SA02 program. Armata's lead clinical candidate, AP-SA02, is being developed as an adjunctive treatment for complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus or methicillin-resistant S. aureus. The additional funding will be used to support the Phase 3 clinical program for AP-SA02.

Armata Pharmaceuticals' AP-SA02 Receives FDA Breakthrough Therapy Designation

Armata Pharmaceuticals announced that the U.S. FDA has granted Breakthrough Therapy designation to AP-SA02, the company's intravenously administered Staphylococcus aureus multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin-resistant S. aureus. Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential for substantial improvement over available therapies.

Armata Pharmaceuticals Publishes New Paper in Journal of Molecular Biology

Armata Pharmaceuticals announced a paper in the Journal of Molecular Biology, a peer-reviewed journal. The publication, titled "Insights into Genome Ejection by a Therapeutic phiKMV-like Bacteriophage," presents an integrative structural atlas of Ar-KM, a phiKMV-like bacteriophage that targets Pseudomonas aeruginosa, the pathogen addressed by Armata's AP-PA02 program. AP-PA02 is an inhaled bacteriophage product candidate that has completed Phase 2 clinical studies in both cystic fibrosis and non-CF bronchiectasis patients with chronic pulmonary P. aeruginosa infection. Using cryo-electron microscopy, proteomics, and bioinformatics, the researchers captured three distinct states of the phage particle from a single purified preparation and built atomic models for eleven structural proteins at near-atomic resolution. The work explains how Ar-KM keeps its genome securely packaged before infection, identifies an enzyme activity that helps the phage penetrate the bacterial cell envelope, and characterizes a previously unrecognized protein that enables the coordinated release and delivery of the genome into the bacterium.